Status:
COMPLETED
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the stud...
Eligibility Criteria
Inclusion
- Patients who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.
- Patients who are capable of giving informed consent
Exclusion
- Patients failed to discontinue the Study 311-10-001 even though patients met the discontinuation criteria.
- Patients who have participated in any other clinical trials , excluding the Study 311-10-001).
Key Trial Info
Start Date :
January 24 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2016
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01475370
Start Date
January 24 2012
End Date
December 22 2016
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Tokyo, Japan